127 related articles for article (PubMed ID: 2490491)
1. [Role of the new beta lactams in severe infections. Imipenem and aztreonam: indications and limitations].
Sánchez C; Garau J
Enferm Infecc Microbiol Clin; 1989; 7 Suppl 1():67-75. PubMed ID: 2490491
[No Abstract] [Full Text] [Related]
2. Aminoglycosides, imipenem, and aztreonam.
Johnson JG; Hardin TC
Clin Podiatr Med Surg; 1992 Apr; 9(2):443-64. PubMed ID: 1586911
[TBL] [Abstract][Full Text] [Related]
3. Imipenem and aztreonam: current role in antimicrobial therapy.
Rice LB; Eliopoulos GM
Curr Clin Top Infect Dis; 1989; 10():109-39. PubMed ID: 2679691
[No Abstract] [Full Text] [Related]
4. Aztreonam: an appraisal.
Neu HC
N J Med; 1986 Jan; Spec No():42-5. PubMed ID: 3485269
[No Abstract] [Full Text] [Related]
5. Symposium on antimicrobial therapy. V. The carbapenems and monobactams.
Greenfield RA
J Okla State Med Assoc; 1993 Feb; 86(2):63-5. PubMed ID: 8331460
[No Abstract] [Full Text] [Related]
6. The newer cephalosporins. Aztreonam and imipenem.
Ennis DM; Cobbs CG
Infect Dis Clin North Am; 1995 Sep; 9(3):687-713. PubMed ID: 7490439
[TBL] [Abstract][Full Text] [Related]
7. [New beta-lactam antibiotics: penems and monobactams].
Swierzy H
Pol Tyg Lek; 1988 Dec 19-26; 43(51-52):1687-90. PubMed ID: 3268823
[No Abstract] [Full Text] [Related]
8. Imipenem-cilastatin sodium.
Roach AC
Crit Care Nurse; 1989 Mar; 9(3):14-8. PubMed ID: 2582800
[No Abstract] [Full Text] [Related]
9. In vitro and in vivo experience with carumonam: a preliminary report.
Kanellakopoulou K; Manta M; Tsagaraki C; Giamarellou H
J Chemother; 1989 Jul; 1(4 Suppl):125. PubMed ID: 16312334
[No Abstract] [Full Text] [Related]
10. Surgery-related infections: a challenge for the physician. Introduction.
Nichols RL
Surg Gynecol Obstet; 1990; 171 Suppl():9-10. PubMed ID: 2244296
[No Abstract] [Full Text] [Related]
11. New developments in carbapenems.
Kattan JN; Villegas MV; Quinn JP
Clin Microbiol Infect; 2008 Dec; 14(12):1102-11. PubMed ID: 19076841
[TBL] [Abstract][Full Text] [Related]
12. [Clinical review and antibacterial effect of aztreonam in infections in obstetrics and gynecology].
Fujimoto S; Makinoda S; Tanaka T; Ichinohe K
Jpn J Antibiot; 1985 Dec; 38(12):3513-9. PubMed ID: 3841730
[TBL] [Abstract][Full Text] [Related]
13. Aztreonam: early clinical studies in New Jersey.
Johnson ES; Eng RK; Perez EM; Smith LG
N J Med; 1986 Jan; Spec No():26-9. PubMed ID: 3513061
[No Abstract] [Full Text] [Related]
14. In vitro activity of ciprofloxacin in comparison with aztreonam, imipenem, and ceftazidime against multiply resistant strains.
Nemes G; Stolle D; Nemes P
Chemioterapia; 1987 Jun; 6(2 Suppl):133-5. PubMed ID: 3334552
[No Abstract] [Full Text] [Related]
15. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
Piddock LJ; Johnson MM; Webber MA
J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
[TBL] [Abstract][Full Text] [Related]
16. Aztreonam--an overview.
Hopefl AW
Drug Intell Clin Pharm; 1985 Mar; 19(3):171-5. PubMed ID: 3884302
[TBL] [Abstract][Full Text] [Related]
17. Aztreonam: worldwide clinical experience with the first monobactam.
Bendush CL; Henry SA; Newman TJ; Swabb EA
N J Med; 1986 Jan; Spec No():30-6. PubMed ID: 3513062
[No Abstract] [Full Text] [Related]
18. [A comment on the contribution by H. Rosin: "Beta-lactam antibiotics"].
Cullmann W; Opferkuch W
Internist (Berl); 1989 Sep; 30(9):628-9. PubMed ID: 2807787
[No Abstract] [Full Text] [Related]
19. In-vitro susceptibility to aztreonam.
Lim VK
Malays J Pathol; 1988 Aug; 10():61-4. PubMed ID: 3252078
[No Abstract] [Full Text] [Related]
20. [Imipenem resistance in Gram-negative rods and its consumption between 1999 and 2005].
Gospodarek E; Gierlotka K; Deptuła A; Michalska A
Med Dosw Mikrobiol; 2007; 59(3):231-40. PubMed ID: 18078118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
